Diabetes Mellitus, Type 1, Diabetes Mellitus, Type I, Presymptomatic Diabetes Type 1 (Stage 1)
Conditions
Keywords
PreTreg, Tregs, Prediabetes, presymptomatic
Brief summary
The main purpose of the study is to check: * Can therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or an anti-CD20 antibody preparation (rituximab) be successfully used in children with pre-diabetes to treat or delay type 1 diabetes? * Is therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or a preparation of antiCD20 antibodies (rituximab) safe for children with pre-diabetes, and what side effects may be associated with it? The study will include patients at high risk for type 1 diabetes whose laboratory tests have confirmed preserved normal/high insulin production. First (part 1 of the study), tests will be performed to determine the risk of the disease (determination of autoantibodies that characterize the autoimmune background). In order to confirm the effectiveness of the therapy, not all patients will receive the study treatment. The study will be a so-called blinded randomized trial. This means that in this trial, all participants will undergo the same study procedures, but the participant will be randomly assigned to one of four (4) groups that will receive different treatment regimens before entering the study. The participant will be randomly assigned to one of four groups: * Group I will receive a preparation of regulatory cells (Tregs lymphocytes) along with a preparation of antiCD20 antibodies, * Group II will receive a preparation of regulatory cells (Tregs lymphocytes) together with an inert substance (placebo) * Group III will receive a preparation of antiCD20 antibodies along with a sham treatment (inert substance) * Group IV will receive an agent containing an inert substance and sham treatment. Approximately 150 patients aged 3-18 who are at risk of developing type 1 diabetes will be enrolled in the study, which will last up to 96 months. Each enrolled participant will remain in the study for up to five years.
Detailed description
Participants: screening of approximately 2500 high-risk subjects will be conducted until no less than 150 participants with confirmed stage 1 (preclinical) type 1 diabetes mellitus are randomized; randomization 2:1:1:2; 50 participants treated with Tregs and anti-CD20 antibody; 25 participants treated with Tregs; 25 participants treated with anti-CD20 antibody; control: 50 participants receiving placebo and sham Tregs. Inclusion of participants: up to 36 months. Trial intervention: Total duration of the trial intervention for each participant will be approximately 3 Months. After completion of the trial intervention, participants will be monitored at the sites for the onset of type 1 diabetes mellitus for a maximum of five years counting from the first dose of Tregs. Follow-up time: post-treatment observation of all participants to 57 months (day "0" is the day of administration of the first dose of Treg/sham preparation). Trial time: 96 months. Trial type: Prospective randomized (phase 2), placebo-controlled, parallel group, blinded trial. Blinding: The following roles indicated below will not be made aware of the treatment group assignment during the trial: * participant * legal representatives * site staff excluding pharmacists (applies to anti-CD20only)
Interventions
BIOLOGICALex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)
regulatory T cells with the phenotype CD3(+)CD4(+)CD25(high)CD127(-)doublet(-)lin(-)
BIOLOGICALAnti-CD20 (rituximab)
rituximab
OTHERPlacebo
intrevenous 0,9% NaCl
OTHERTreg sham
intrevenous 0,9% NaCl
Sponsors
PolTREG S.A.
Invicta Sp. z o.o.
Medical Research Agency, Poland
Clinmark Clinical Research
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Blinding: The following roles indicated below will not be made aware of the treatment group assignment during the trial: * participant * legal representatives * site staff excluding pharmacists (applies to anti-CD20 only)
Intervention model description
Trial type: Prospective randomized, placebo-controlled, parallel group, blinded trial. Control method: placebo, active comparator, sham procedure.
Eligibility
Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Age 3-18 2. 5 ≤ BMI ≤ 95 percentile (acc. to OLAF, or WWF in the case of children under six years old) with a lower weight threshold of 20 kg 3. Venous plasma glucose levels \< 100mg% at fasting (70 to 100 mg/dl) and normal glucose tolerance test (at 120 minutes glycaemia \<140 mg/dl) (acc. to PTD) 4. Insulin independence 5. C-peptide levels ≥ 1.0 ng/ml (central laboratory limit of normal) in fasting and post-stimulation tests increase ≥ 100% 6. Participant has not yet been diagnosed with stage 2 or 3 type 1 diabetes mellitus (no history of dysglycemia, no history of clinical symptoms of type 1 diabetes mellitus) 7. HbA1c level (%) \<5,7% (acc. to ADA) 8. Positive autoantibody titres (ICA, IAA, GAD, IA-2/ICA512, ZnT8) - low titers of two or more antibodies (2 times the normal\* or higher); if high titer of one of the antibodies (≥ 4 times the norm, not applicable to ICA) re-screening allowed (the participant can be included in the trial only after confirming two or more antibodies) 9. Ability to give informed consent by the child's legal representatives (and the child himself or herself if he or she is over the age of 13 at the time of the trial \[according to local law\]) 10. Ability of the child's legal representatives to manage diabetes, defined as blood glucose levels control at least three times a day and the ability to dose insulin correctly. 11. Venous access to guarantee blood donation \* Standard defined depending on the method used
Exclusion criteria
12. Refusal to participate in the trial or lack of a signed informed consent form 13. Suspicion or diagnosis for a type of diabetes other than type 1 diabetes mellitus 14. Age under 3 or above 18 15. IgA deficiency or history of other diagnosed immunodeficiency (max. 7 infections/year allowed, and the prognosis should indicate that the patient will remain in the study throughout its duration) 16. C-peptide levels \< 1.0 ng/ml fasting and in post-stimulation tests increase \< 100% 17. Glucose levels in venous blood ≥ 100mg% fasting 18. Glucose levels in venous blood after 1 and 2 hours in OGTT ≥ 200mg% 19. Glycated hemoglobin level (HbA1c) in venous blood ≥ 5,7% 20. BMI \< 5th percentile or \> 95th percentile for age, or body weight \< 20 kg 21. History of hypersensitivity to anti-CD20 or other components of the preparation 22. History of hypersensitivity to penicillin and/or streptomycin 23. Past or active infection with HBV, HCV, HIV, HTLV I/II, mycobacterium tuberculosis, syphilis. Laboratory evidence of infection without the need for clinical signs and symptoms is sufficient for diagnosis. 24. Active infection with the EBV or CMV virus (positive IgM) 25. Any fungal, parasitic, viral, or bacterial infection 26. History of past or active cancer 27. Anemia, lymphopenia, neutropenia, or thrombocytopenia defined as a blood cell count below the lower limit of normal for age found within the last 6 weeks prior to trial inclusion 28. Elevated thrombotic activity/history of thrombosis episode 29. Any disease prior to inclusion in the trial currently requiring medication for more than 3 months in history 30. Diagnosed autoimmune disease other than type 1 diabetes mellitus, including a history of Hashimoto's disease and coeliac disease 31. Taking anti-diabetic medication (including insulin) in the last 4 weeks prior to trial inclusion 32. History of retinopathy 33. History of hypertension 34. Current or history of albuminuria 35. For women in childbearing potential/menstruating women: pregnancy (from medical interview) or unwillingness to exercise sexual restraint or use effective forms of contraception for the duration of the trial and up to 4 months after completion, if applicable. The following contraceptive methods are acceptable: bilateral fallopian tube closure, sterilization in men, appropriate use of hormonal contraception that inhibits ovulation, hormone-releasing IUDs, and copper IUDs, male or female condoms with spermicide; and cap, uterine disc, or sponge with spermicide. 36. Breastfeeding 37. For males over 15 years of age: expressed intention to have offspring or donate sperm during the trial or within 4 months after the end of the trial, if applicable 38. Excessive anxiety of the participant or his/her legal representatives regarding the procedures used in the trial 39. Any medical problem that, in the opinion of the investigator, may adversely affect the participant's health if included in the trial 40. Legal representatives and/or children over the age of 15 with an identified alcohol and/or psychoactive substance addiction 41. History of disease of unknown etiology 42. History of Creutzfeldt-Jacob disease 43. History of progressive dementia or degenerative neurological disease, including of unknown origin 44. History of taking hormones derived from the human pituitary gland (e.g., growth hormone) 45. Treatment with immunosuppressants 46. History of corneal, scleral, and dural transplant or undocumented neurosurgery 47. History of occurrence of risk factors related to the participant's travel, where there is a possibility of exposure to regional infectious diseases 48. Physical signs that indicate the risk of an infectious disease 49. History of xenogeneic transplant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| % of participants in each group who are still in stage 1 type 1 diabetes mellitus, i.e., presence of autoantibodies and normoglycemia or in stage 2 type 1 diabetes mellitus, i.e., presence of autoantibodies, dysglycemia or stage 3 at the end of the trial | From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60 | To assess the safety and efficacy of the treatment used in the separate groups of participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/Tregs sham) |
| Number of adverse events reported 1 year, 2 years after the first dose of Tregs and at the end of the trial comparing to control arms | From enrollment to the end of participation in the trial at month 60 (day "0" is the day of administration of the first dose of Treg preparation) | To assess the safety and efficacy of the treatment used in the separate groups of participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/Tregs sham) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pace of diabetes development. Total number of days from the date of diagnosis of stage 2 to the date of onset of full-blown type 1 diabetes mellitus (stage 3 of type 1 diabetes mellitus) in each group (normalized to the number of person/days in each grou | From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60 | Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function |
| Number of days from day 0 to the day of first dysglycemia (stage 2 of type 1 diabetes mellitus) in each group | From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60 | Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function |
| Cumulative diabetes incidence [only the progression to stage 3 considered as diabetes incidence] | From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60 | Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function |
| C-peptide levels [fasting/post MMTT stimulation (AUC)] 1 year, 2 years after the first dose of Tregs and then annually until the end of the trial comparing to control arms | From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60 | Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function |
| Daily average dose of insulin per kg body weight (DDI) 1 year, 2 years after the first dose of Tregs, and annually thereafter until the end of the trial in each arm of the trial | From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60 | Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function |
| Number of participants per arm in remission 1 year, 2 years after the first dose of Tregs, and annually thereafter until the end of the trial, [remission defined as daily insulin dose is less than 0.5U/kg/day with an HbA1c level less than 6.5%] | From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60 | Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function |
| Assessment of the incidence and severity of adverse events associated with the administration of Treg preparation or anti-CD20 antibody, primarily the effects of immunosuppression: incidence of infections of any etiology and de novo tumors detected | From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60 | Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function |
Countries
Poland
Contacts
CONTACTMarta Druch, Clinical Trial Director
CONTACTKatarzyna Karpinska, Sr Clinical Trial Specialist
STUDY_DIRECTORPiotr Trzonkowski, Prof
PolTREG S.A.
PRINCIPAL_INVESTIGATORArtur Bossowski, Prof
Uniwersytecki Dzieciecy Szpital Kliniczny Im. L. Zamenhofa W Bialymstoku
STUDY_CHAIRWojciech Mlynarski, Prof
Uniwersytet Medyczny W Lodzi
Outcome results
None listed